Austin MA. Triacylglycerol and coronary heart disease. Proc Nutr Soc 1997; 56:667-670.

Avogaro P, Rubba P, Mancini M. Smoking and cardiovascular events: biological links. Cardiovasc Risk Factors 1993; 3:373-378.

Bellamy MF, McDowell IFW. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis 1997; 20:307-315.

Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.

Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223:405-418.

Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995. Circulation 1996; 94:2013-2020.

de Divitiis M, Rubba P. Cholesterol-lowering and vascular reactivity in relation to coronary heart disease. Nutr Metab Cardiovasc Dis 1999; 9:133-142.

de Lorgeril M, Salen P, Martin JL et al. Mediterranean diet, traditional risk factors, and rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99:779-785.

Deckelbaum RJ. Structure and composition of human plasma lipoproteins. In: Atherosclerosis: Biology and Clinical Science. London: Churchill Livingstone, 1987;251-255.

Diaz MN, Frei B, Vita JA et al. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337:408-416.

Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.

Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet 1999; 353(Suppl II):5-9.

Fuster V, Ross R, Topol EJ. Atherosclerosis and Coronary Artery Disease. Volume One. Philadelphia: Lippincott Williams and Wilkins; 1996.

Gaziano JM, Hennekens CH, O'Donnell CJ et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96:2520-2525.

Glagov S, Weisenberg E, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316:1371-1375.

Iannuzzi A, Wilcosky T, Mercuri M et al. Ultrasonographic correlates of carotid atherosclerosis in transient ischemic attacks and stroke. Stroke 1995; 26:614-619.

Johannesson M, Jonsson B, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997; 336:332-336.

Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000; 32(Suppl 1):78-84.

Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275:1571-1576.

Mackness MI, Mackness B, Durrington PN et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998; 9:319-324.

Mancini M, Cortese C, Pauciullo P et al. [Hyperlipidemias: Clinical, Physiology and Therapy.] Rome: Il Pensiero Scientifico Editore; 1991.

Mercuri M, Bond G, Sirtori CR et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101:627-634.

O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340:14-22.

Oliver MF, Heady JA, Morris JN et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40:1069-1118.

Oliver MF, Heady JA, Morris JN et al. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol; final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984; 2:600-604.

Oschry Y, Olivecrona T, Deckelbaum RJ et al. Is hypertriglyceridemic very low density lipoprotein a precursor of normal low density lipoprotein? J Lipid Res 1985; 26:158-167.

Pedersen TR, Wilhelmsen L, Faergeman O et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 2000; 86:257-262.

Pickin DM, McCabe CJ, Ramsay LE et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999; 82:325-332.

Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97:596-601.

Robinson K, Arheart K, Refsum H et al. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery diseases. Circulation 1998; 97:437-443.

Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.

Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.

Shepherd J. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study. Am J Cardiol 2001; 87(Suppl):19B-22B.

Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.

Stary HC. Natural history and histological classification of atherosclerotic lesions. An update. Arterioscler Thromb Vasc Biol 2000; 20:1177-1178.

Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 1999; 144:285-301.

Strong JP, Malcom GT, Oalmann MC. Environmental and genetic risk factors in early human atherogenesis: lessons from the PDAY study. Pathol Int 1995; 45:403-408.

Szucs TD. Pharmaco-economic aspects of lipid-lowering therapy: is it worth the price? Eur Heart J 1998; 19(Suppl M):M22-M28.

The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart diseases. JAMA 1984; 251:351-364.

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365-374.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.

Tribble DL. Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E and beta-carotene. A statement for healthcare professionals from the American Heart Association. Circulation 1999; 99:591-595.

Tunstall-Pedoe H, Kuulasmaa K, Mähönen M et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Lancet 1999; 353:1547-1557.

Tyroler HA. Coronary heart disease epidemiology in the 21st century. Epidemiol Rev 2000; 22:7-13.

Virmani R, Kolodgie FD, Burke AP et al. Lessons from sudden coronary death. A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262-1275.

Winniford MD. Smoking and cardiovascular function. J Hypertens 1990; 9(Suppl 5):S17-S23.

Wood D, de Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998; 19:1434-1503.